Clinical Trial Update: Ranibizumab for the Inhibition of Neovascularization in Pterygia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ranibizumab for inhibition of neovascularization in pterygium has completed, focusing on safety and early signals of effect.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University of Miami | Conditions: Pterygium | Phase 1 | Status: COMPLETED